Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 5/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19498563 | 0.87 | MAPT (0.34) | MAPTHSP90AB1LMNATP53POLB | |
| SCHEMBL19498172 | 0.85 | MAPT (0.35) | MAPTHSP90AB1LMNATP53POLB | |
| SCHEMBL19498168 | 0.82 | MAPT (0.41) | MAPTHSP90AB1LMNATP53POLB | |
| SCHEMBL19498565 | 0.79 | MAPT (0.35) | MAPTHSP90AB1LMNATP53POLB | |
| SCHEMBL19498179 | 0.79 | HSP90AB1 (0.47) | TSHRALDH1A1MAPTKMT2AHSP90AB1 | |
| SCHEMBL19498180 | 0.78 | MAP4K1 (0.34) | MAPTHSP90AB1LMNAPOLB | |
| SCHEMBL19498167 | 0.78 | DYRK1A (0.36) | ALDH1A1MAPTHSP90AB1LMNATP53 | |
| SCHEMBL19498196 | 0.77 | CHRM3 (0.33) | KMT2A | |
| SCHEMBL24920540 | 0.74 | LMNA (0.47) | MAPTHSP90AB1LMNATP53POLB | |
| SCHEMBL19498175 | 0.74 | HSP90AA1 (0.38) | TSHRHPGDALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | TSHR 2685/4885HPGD 4411/4885ALDH1A1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.